Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas R Fleming

Showing results (31-40 of 109) with videos related to

Pageof 11
Sort By:
Statistics in Medicine|September 27, 2002
Monitoring clinical trials: issues and controversies regarding confidentialityThomas R Fleming, Susan Ellenberg, David L DeMets
Clinical Trials (London, England)|April 10, 2018
Data Monitoring Committees: Current issuesThomas R Fleming, Susan S Ellenberg, David L DeMets
JAMA|February 28, 2020
When Can Intermediate Outcomes Be Used as Surrogate Outcomes?David L DeMets, Bruce M Psaty, Thomas R Fleming
Biostatistics (Oxford, England)|June 22, 2017
Discussion: The role, position, and function of the FDA-The past, present, and futureThomas R Fleming, David L Demets, Lisa M McShane
Journal of Allergy and Infectious Diseases|January 10, 2022
Monitoring clinical trials in infectious diseasesDavid L DeMets, Thomas R Fleming, Susan S Ellenberg
Journal of Nematology|January 23, 2018
Chemosensory Responses of Plant Parasitic Nematodes to Selected Phytochemicals Reveal Long-Term Habituation TraitsThomas R Fleming, Aaron G Maule, Colin C Fleming
JAMA|July 15, 2010
Bias and trials stopped early for benefitSusan S Ellenberg, David L DeMets, Thomas R Fleming
Clinical Trials (London, England)|April 25, 2023
Finding the (biomarker-defined) subgroup of patients who benefit from a novel therapy: No time for a game of hide and seekLisa Meier McShane, Mark D Rothmann, Thomas R Fleming
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 6, 2009
Issues in using progression-free survival when evaluating oncology productsThomas R Fleming, Mark D Rothmann, Hong Laura Lu
Science and Engineering Ethics|November 25, 2016
Institutional Responsibility and the Flawed Genomic Biomarkers at Duke University: A Missed Opportunity for Transparency and AccountabilityDavid L DeMets, Thomas R Fleming, Gail Geller, et al.
Pageof 11

Showing results (31-40 of 109) with videos related to

Sort By:
Pageof 11
Statistics in Medicine|September 27, 2002
Monitoring clinical trials: issues and controversies regarding confidentialityThomas R Fleming, Susan Ellenberg, David L DeMets
Clinical Trials (London, England)|April 10, 2018
Data Monitoring Committees: Current issuesThomas R Fleming, Susan S Ellenberg, David L DeMets
JAMA|February 28, 2020
When Can Intermediate Outcomes Be Used as Surrogate Outcomes?David L DeMets, Bruce M Psaty, Thomas R Fleming
Biostatistics (Oxford, England)|June 22, 2017
Discussion: The role, position, and function of the FDA-The past, present, and futureThomas R Fleming, David L Demets, Lisa M McShane
Journal of Allergy and Infectious Diseases|January 10, 2022
Monitoring clinical trials in infectious diseasesDavid L DeMets, Thomas R Fleming, Susan S Ellenberg
Journal of Nematology|January 23, 2018
Chemosensory Responses of Plant Parasitic Nematodes to Selected Phytochemicals Reveal Long-Term Habituation TraitsThomas R Fleming, Aaron G Maule, Colin C Fleming
JAMA|July 15, 2010
Bias and trials stopped early for benefitSusan S Ellenberg, David L DeMets, Thomas R Fleming
Clinical Trials (London, England)|April 25, 2023
Finding the (biomarker-defined) subgroup of patients who benefit from a novel therapy: No time for a game of hide and seekLisa Meier McShane, Mark D Rothmann, Thomas R Fleming
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 6, 2009
Issues in using progression-free survival when evaluating oncology productsThomas R Fleming, Mark D Rothmann, Hong Laura Lu
Science and Engineering Ethics|November 25, 2016
Institutional Responsibility and the Flawed Genomic Biomarkers at Duke University: A Missed Opportunity for Transparency and AccountabilityDavid L DeMets, Thomas R Fleming, Gail Geller, et al.
Pageof 11